Testing a new protein drug with standard treatment for new glioblastoma
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests whether adding a drug called L19TNF to standard chemoradiotherapy is safe and may work better than standard treatment alone for newly diagnosed glioblastoma. If you qualify, you would be closely monitored for side effects and treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your glioblastoma has been newly diagnosed and confirmed by pathology (tissue testing).
- You can do daily activities fairly well (Karnofsky score 70% or higher).
- Your HIV, hepatitis B, and hepatitis C tests are negative (or hepatitis C is not active).
- If you can become pregnant, you must have a negative pregnancy test and use highly effective birth control; if you’re a man who can father children, you must use two birth-control methods during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental drug called liposomal transcrocetin (L-TC) to the standard treatment of radiation and temozolomide chemotherapy helps people with newly diagnosed glioblastoma. It aims to see if the combination improves outcomes compared to standard care alone.
This Phase 1/2 study tests whether “glutamate inhibitor” medications can be safely added for newly diagnosed glioblastoma, and how they affect treatment outcomes. It’s designed for adults who will also receive the standard chemo‑radiation plan with temozolomide.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This study looks at how your immune system reacts to brain tumor surgery and standard treatment, using a special dye to help the surgeon see the tumor better. It aims to find out if this approach can improve outcomes for people with glioblastoma.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.